IP Library Granted Patent US 9,580,419
Granted Patent B2
US 9,580,419 · App. 14/799,777 · Granted Feb 28, 2017

Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors

Inventors: James D. Rodgers (Landenberg, PA); Haisheng Wang (Hockessin, DE); Andrew P. Combs (Kennett Square, PA); Richard B. Sparks (Wilmington, DE)
Assignees: Incyte Corporation; Incyte Holdings Corporation
C07D471/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,580,419
App. No.
14/799,777
Granted
Feb 28, 2017
Kind
B2
Abstract

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Claims (7)

1. A method of treating dermatitis in a patient, comprising topically administering to said patient a therapeutically effective amount of a compound which is 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}-3-oxo-propionitrile, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-piperidin-1-yl}-3-oxo-propionitrile is topically administered.

3. The method of claim 1 , wherein the compound is administered in the form of a transdermal patch.

4. The method of claim 1 , wherein the compound is administered in the form of an ointment.

5. The method of claim 1 , wherein the compound is administered in the form of a lotion.

6. The method of claim 1 , wherein the compound is administered in the form of a cream.

7. The method of claim 1 , wherein the compound is administered in the form of a gel.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2015
From: RODGERS, JAMES D.; WANG, HAISHENG; COMBS, ANDREW P.; SPARKS, RICHARD B.
To: INCYTE CORPORATION
Reel/Frame 037391/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2015
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 037392/0173 →
Continuity (8)
Continuation 14255092 · Apr 17, 2014
Continuation 13889618 · May 8, 2013
Continuation 13245333 · Sep 26, 2011
Continuation 11980314 · Oct 30, 2007
Continuation 11313394 · Dec 21, 2005
Provisional Application 60638474 · Dec 22, 2004
Provisional Application 60726289 · Oct 13, 2005
Related Publication 20150315185A1 · Nov 5, 2015